The most accepted definition of DA resistance is failure to normalize PRL levels with CAB doses from ≥1.5 to 2.0 mg per week and, in the case of macroprolactinoma, failure to achieve tumor size reduction of 30% to 50% (35-37). Here, PRL is linked to neoplasm.